



CWMD/MCDC Other Transactions

CBDAIF UPDATE



PROTECTING THE JOINT FORCE

Mr. Jeff Megargel

Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense

15 August 2019

UNCLASSIFIED
Distribution Statement
A: Approved for public
release; distribution
is unlimited.

AGENDA

- Background
- CWMD OT Workload
- MCDC Workload
- OT Lessons Learned
- The Basket Provision
- Transitioning to Follow-on Production
- Significant Events
- What's Coming



BACKGROUND

The JPEO-CBRND sponsors two consortium based other transaction agreements.


- Medical CBRN Defense Consortium (MCDC)
 - Estimated ceiling of \$10B with 20 year PoP
 - Established May 2016
- Countering Weapons of Mass Destruction (CWMD)
 - Estimated ceiling of \$10B with ten year PoP
 - Established November 2017
- Both other transactions are scoped to fulfill CWMD / CBRNE prototyping requirements for any Federal agency with OT authority.

*The MCDC has awarded 26 prototyping projects and the CWMD OT has awarded **57**.*




CWMD OT WORKLOAD BREAKDOWN

FY18 Workload by Customer



Total Projects: 22

FY19 Workload by Customer




Total Projects: 95

Workload increased by 231% from FY18 to FY19
External Organizations account for over 40% of workload
12 additional projects are projected for FY19




MCDC OT WORKLOAD BREAKDOWN

FY18 Workload by Customer



Total Projects: 6

FY19 Workload by Customer



Total Projects: 31

As of 20 August, MCDC now has 35 projects in process.



OT Lessons Learned & Best Practices

- DoD now emphasizing insertion of logistics concerns into OT prototyping phase agreement scope
 - Evolving approach to ensure logistics support will be in scope for follow-on
- Industry can elect to use Fixed Amount or Expenditure Based pricing
 - Reporting should be appropriate to complexity of effort
- Deliverables / milestone schedule and intellectual property assertions must be aligned
 - PMO engaging in SOW negotiations to reduce time to approval
- Modifications happen
 - Initial scope for each agreement should be broad



THE BASKET *(IS IT JUST A MIRAGE?)*

- Both JPEO-CBRND sponsored OTAs have a basket provision that allows any white paper proposals that were evaluated as acceptable to remain valid for up to 36 months.
 - Any DoD, HHS, or DHS user may “pull” a white paper out of the basket and begin negotiating the SOW.
 - Requires concurrence from original requirements office
 - One time use only
 - Assume PALT of 60 days (must be within 36 month window)

*The CWMD OT has awarded five projects from the basket; MCDC has awarded three with **five** more in negotiation.*



CWMD OT BASKET PULL ACTIVITY

RPP	Project	Status
RPP-18-01	CWMD1801-001	Awarded
RPP-18-01	CWMD1801-004	Awarded
RPP-18-06	CWMD1810-003	Awarded
RPP-18-14	CWMD1817 ¹	Pre-Award
RPP-18-21	CWMD1824-021	Awarded
RPP-18-26	CWMD1829-003	Awarded

¹The CWMD 1817 basket pull will be awarded in FY19.



MCDC OT BASKET PULL ACTIVITY

RPP	Project	Status
17-01-02	17-01-02-004	Awarded
18-04-14	18-04-14-003	Awarded
18-04-14	18-04-14-007	Awarded
18-04-11	18-04-11-004	Pre-Award
18-04-13	18-04-13-002	Pre-Award
18-04-13	18-04-13-003	Pre-Award
18-06-17	18-06-17-001	Pre-Award
19-05	19-05-001	Pre-Award
19-05	19-05-007	Pre-Award



IS IT DIFFICULT TO OBTAIN FEEDBACK?

- ATI automatically provides or makes available feedback (in BIDS) to the POC listed in the proposal or white paper regardless of selection decision.
 - The feedback letter is a verbatim copy of the evaluation of each proposal or white paper.
- When ATI receives requests for additional feedback, they refer each offeror to the AOR listed in the RPP.
 - On exceedingly rare occasions, the OT PMO has been asked to assist in coordinating provision of more detailed feedback.

If an offeror experiences difficulty obtaining additional feedback, they need only contact ATI or the OT PMO for assistance.



Transitioning to Follow-On Production

- JPEO-CBRND conducting initial planning for follow-on production
 - Most projects will use a FAR based approach
 - APG-EA planning to execute first stand-alone follow-on other transactions (FOT)
 - Will follow USD A&S requirements for determining eligibility for FOT
- As long as competitive procedures were utilized [for the prototype project], the participant successfully completed the prototype, and the solicitation and original agreement allowed for a follow-on for production contract or other transaction, a sole-source award may be made to a single participant. *USD A&S Other Transaction Guide, Section E.4., November 2018.*



Significant Events

- PMO consolidation effective 1 June 2019
 - MCDC and CWMD OTs managed in one PMO
- Combined general membership meeting scheduled for 12-13 November 2019 in Rockville, MD
 - Emphasizing collaboration between the DHS CWMD Office and the JPEO-CBRND
 - Will include DTRA, HHS and CDC CB center among others
 - Tentative agenda includes OT related training, business opportunities and one-on-one sessions



What's Coming

- Multiple prototyping projects will transition to follow-on production in FY20
 - Focused on smooth transition between contracting activities
 - Sorting out legal aspects and engagement with incumbents
- Increased focus on training and forecasting
 - FY19 training efforts have really paid off
 - Effective communication of opportunities is still work in progress
- Expand collaboration with DTRA and DHS CWMD Office

Anticipate changes in the usage rates associated with each OT consortium.



POINTS OF CONTACT

Thomas Dickson

Chief Contracting Officer

thomas.a.dickson4.civ@mail.mil

Michele Boardwine

Director, JCMO

michele.l.boardwine.civ@mail.mil

Jeff Megargel

Program Manager

410.417.2323

jeffrey.w.megargel.civ@mail.mil

Barry Sayer

Senior Contract Integrator

301.619.2709

barry.g.sayer.civ@mail.mil




Backups



CWMD PERFORMANCE

Days to Award



Days in Stage

RPP Phase
 Source Selection Phase
 Negotiations Phase
 Award Phase



MCDC PERFORMANCE

JpDM	RPP	Sub-Objective	Sub-Objective Area	PROJECT NAME (SUBOBJECTIVE)	FINAL COST Incl Fee	PALT
MCS	16-01	16-01	PREVENTION	Fill/Finish of VEE Virus like particle (BLP) Bulk Drug Product	\$699,102.54	169
MCS	16-01	16-01-02	PREVENTION	Development of Monoclonal Antibody MCS against Aerolized Botulinum Toxin Serotypes A and B	\$44,114,567.00	100
MCS	16-02	16-02-05	PREVENTION	VEE Monovalent VLP Phase I Clinical Study	\$5,208,172.41	203
MCS	16-02	16-02-03	TREATMENT	Development of a Dual Drug Agency Delivery Device (D4) AutoInjector	\$24,490,355.13	375
MCS	17-02	17-02-05	DETECTION	Man-Portable Diagnostics System (MPDS)	\$38,386,565.29	200
MCS	17-02	17-02-04	PREVENTION	Dev. Of Multiple Target Single Vector Vaccine Prototype against Aerosolized Equine Encephalitic viruses including VEE Virus	\$ 37,979,997.96	396
JSTO	18-01	18-01-03	PREVENTION	Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents	\$ 11,603,731.95	301
MCS	17-03	17-03-07	DETECTION	Man-Portable Diagnostics System (MPDS) - Expanded Scope	\$ 59,636,949.63	434
JSTO	18-04	18-04-15	DETECTION	Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the Plague	\$ 4,694,645.80	144
MCS	18-02	18-02-04	TREATMENT	Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic Evaluations	\$ 249,496.80	245
MCS	17-03	17-03-08	DETECTION	Chemical Exposure In Vitro Diagnostics (Chem DX)	\$ 9,943,280.10	481
JSTO	18-04	18-04-15	DETECTION	Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the Plague	\$ 1,359,270.40	172
JSTO	18-01	18-01-01	PREVENTION	Rapid Single-molecule-based Diagnostic platform Assessment of Pathogen Susceptibility to Anti-microbial Agent	\$ 3,488,708.88	411
JSTO	17-01	17-01-02	TREATMENT	Development of Efficacious Antiviral Countermeasures (EAC)	\$ 9,331,616.00	196
JSTO	18-01	18-01-01	PREVENTION	Rapid Single-molecule-based Diagnostic platform Assessment of Pathogen Susceptibility to Anti-microbial Agent	\$ 5,997,583.00	419
JSTO	18-06	18-06-16	TREATMENT	Novel Therapeutics for Multidrug Resistant Bacterial Bio threat Pathogens	\$ 8,894,774.00	344
JSTO	18-03	18-03-08	TREATMENT	Proof of Concept	\$ 2,236,389.00	388
JSTO	18-03	18-03-08	TREATMENT	Proof of Concept	\$ 1,940,766.00	388
JSTO	18-03	18-03-07	TREATMENT	Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents	\$ 10,037,014.00	402
PRISM	18-05	18-05-19	PREVENTION	ADAMANT 2 Development of monoclonal antibodies as medical countermeasures against aerosolized Plague infection.	\$ 130,267,841.00	344
JSTO	18-04	18-04-10	DETECTION	Assay Development for the Identification of Markers of Venezuelan Equine Encephalitis Virus Infection in Animal Models	\$ 2,790,291.63	370
MCS	16-01	16-01	PREVENTION	Fill/Finish of VEE Virus like particle (BLP) Bulk Drug Product	\$699,102.54	169

UNCLASSIFIED